Navigation Links
HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
Date:6/17/2013

gned to confirm observations from ENDURANCE that sites adhering to more regular monitoring and management of patient blood pressure witnessed a notably lower incidence of neurological events.  

In this supplemental cohort, HeartWare will enroll up to an additional 240 HeartWare HVAD patients, as well as up to an additional 120 control patients using a randomization scheme consistent with the ENDURANCE protocol.  Patients will be followed for 12 months after implant.  HeartWare intends to incorporate the data from this new cohort into an anticipated Pre-Market Approval (PMA) Application seeking approval of the HeartWare System for the Destination Therapy indication.  

Patient enrollment in this supplemental cohort can commence at the 50 centers participating in the ENDURANCE clinical trial, following edits to the protocol as prescribed by FDA and Institutional Review Board approvals at each of the centers.

On November 20, 2012, FDA granted approval of the HeartWare System for the Bridge-to-Transplant indication.  Concurrent with approval, the Company commenced a post-approval study (PAS) to assess device performance in a real-world setting.  HeartWare's PAS is a registry consisting of 600 patients who receive an HVAD and an additional 600 control patients derived from a contemporaneous group of continuous flow, intra-corporeal LVAD patients entered into the INTERMACS database.  HeartWare expects enrollment for both arms of the PAS will be complete by year's end. 

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally requir
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
2. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
3. HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
4. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
5. HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
6. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
7. HeartWare Schedules First Quarter Conference Call And Webcast
8. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
9. HeartWare International, Inc. Announces Public Offering of Common Stock
10. HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
11. HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
(Date:3/26/2015)... HOUSTON , March 26, 2015  The ... of a study independently conducted by the Department ... Japan have been published. ... compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant ... colorectal metastasis of the liver. ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
...  Scientists at The Scripps Research Institute have shown that an ... of cocaine. The findings could lead to human clinical trials ... in case of emergency. Cocaine is involved in more than ... in the United States. The findings, reported recently ...
... FRANCISCO, April 18, 2012 Although adherence to hypertension ... total costs of care are higher for adherent patients ... a new study from pharmacy benefit manager Prime Therapeutics ... Academy of Managed Care Pharmacy (AMCP),s 24th Annual Meeting ...
Cached Medicine Technology:Scripps Research Institute Scientists Develop Antidote for Cocaine Overdose 2Scripps Research Institute Scientists Develop Antidote for Cocaine Overdose 3Scripps Research Institute Scientists Develop Antidote for Cocaine Overdose 4Hypertension Drug Adherence Associated with Fewer Hospitalizations and Lower Medical Costs but Increased Total Care Costs 2
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Pitching speed, ... a history of shoulder and elbow injuries, according to new ... Medicine’s ( AOSSM ) Specialty Day. , “Our findings indicate ... a 20% increase in likelihood of a history of injury, ... with a 12% increase likelihood of a history of injury, ...
(Date:3/28/2015)... 2015 Delaying rotator cuff surgery on ... to research presented today at the American Orthopaedic Society ... “Our study compared results for 170 patients who received ... glenohumeral joint capsule release procedure to relieve stiffness at ... lead author from St. George Hospital in Sydney, Australia. ...
(Date:3/28/2015)... 2015 Andrew Hawley of Vintage Rock Posters ... concert posters. The Who and the Doors played together at ... 1968. According to Hawley, “The Who toured the United States ... college campuses. Perhaps the most famous Who poster was a ... the Doors on August 2, 1968 at the Singer Bowl ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness Celebration ... Conference Center in Chesapeake, Virginia. Each year, ARDX celebrates ... in the Hampton Roads region. The 2015 Women’s History ... Women grow stronger through sharing their stories and learning the ... WWC™ theme is T-talk where we will share a cup ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... A new type of diagnostic imaging - which can ... cancerous - could be used to prevent unnecessary surgery ... A study by Belgian researchers, which will be ... Society,s Annual Congress in Amsterdam, found that the new ...
... in moderate quantities can reduce the risk of asthma, according ... today (25 September 2011) at the European Respiratory Society,s Annual ... a week could reduce the risk of developing the condition. ... of 12 and 41 yrs of age. All participants completed ...
... A major UK trial has produced firm evidence that ... with early breast cancer significantly reduces the risk of ... The treatment, known as synchronous chemoradiation, has minimal adverse ... of life. Findings from the SEquencing of ...
... of the care of patients with rectal cancer have ... chemotherapy and radiotherapy between European countries. The European ... the European CanCer Organisation compared the treatment ... Netherlands who were diagnosed with rectal cancer between 2008 ...
... for patients with bone metastases from advanced prostate cancer ... III study of an alpha-pharmaceutical in these patients has ... research reported today (Saturday) at the 2011 European Multidisciplinary ... Parker, Consultant Clinical Oncologist at the Royal Marsden Hospital, ...
... Sept. 23 (HealthDay News) -- People,s bodies build up vitamin ... black men who live in areas of the United States ... deficiency than whites who live in the same places. ... recommendations need to change. "This study shows that across-the-board vitamin ...
Cached Medicine News:Health News:New diagnostic imaging for lung cancer could prevent unnecessary surgery 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2
... Volks Centralis Direct Laser Lens affords the ... posterior segment of the eye. Utilizing a ... bonded protective glass LaserWindow™ exterior, this special ... other lower profile fundus lenses. Available in ...
... Area Centralis® is excellent for critically ... changes from macular degeneration, retinal vascular ... retinopathy and other retinal conditions. It ... of these conditions providing excellent magnification ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
... This unique 129 diopter contact lens has ... at the slit lamp when traditional non-contact ... views. The Equator Plus delivers an outstanding ... be used with pupils as small as ...
Medicine Products: